Timing of Gemcitabine and Cisplatin Treatment
Author Information
Author(s): Li X M, Tanaka K, Sun J, Filipski E, Kayitalire L, Focan C, Lévi F
Primary Institution: INSERM E 354 ‘Chronothérapeutique des Cancers’ and Université Paris XI, Hôpital Paul Brousse, Villejuif, France
Hypothesis
The study investigates the impact of circadian timing on the therapeutic index of gemcitabine and cisplatin in cancer treatment.
Conclusion
Administering gemcitabine at 11 HALO and cisplatin at 15 HALO significantly improved tolerability and increased median survival in mice.
Supporting Evidence
- Gemcitabine dosing at 11 HALO resulted in significantly less body weight loss compared to 23 HALO.
- Combining gemcitabine and cisplatin at optimal times increased median survival three-fold.
- Neutropenia was more severe when drugs were administered at 23 HALO compared to 11 HALO.
Takeaway
Giving cancer drugs at the right time of day can make them work better and cause fewer side effects.
Methodology
Healthy mice received gemcitabine and cisplatin at various circadian times to assess toxicity and efficacy.
Limitations
The study was conducted in mice, which may not fully represent human responses.
Participant Demographics
Male B6D2F1 mice, 6 weeks old.
Statistical Information
P-Value
P=0.001
Confidence Interval
95% CL, 0800 to 1300
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website